Moreover, dual inhibition of EGFR with an irreversible EGFR inhibitor (afatinib) and the EGFR neutralizing antibody cetuximab has recently shown promising activity in EGFR mutant lung cancers with acquired EGFR TKI resistance that harbor an EGFR T790M mutation [88]. The gene discussed is EGFR; the disease is lung carcinoma.